FDA Clears Hospira's Biosimliar Of Amgen's Epogen
The U.S. Food and Drug Administration on Tuesday approved Hospira's Inc.'s anemia medication Retacrit, a biosimilar of Amgen Inc.'s blockbuster biologic Epogen, bringing the total number of biosimilars approved by the...To view the full article, register now.
Already a subscriber? Click here to view full article